Li Zhen MD

Mr. Li is currently responsible for the antibody discovery and preclinical development of antibody based therapeutics at MabSpace. Mr. Li joined MabSpace in 2013 with more than 12 years industry experience of drug discovery and preclinical development. Before joining MabSpace, he was preclinical development project leaders in Shenogen Pharma, Hutchison Biopharma and Luye Pharma. He was involved in the preclinical study of various novel drugs, including Icaritin and ER-a36 targeting antibody, EGFR/c-Met /RON small molecular TKIs, sustained release microsphere projects at Luye.